Driehaus Capital Management LLC Purchases 135,750 Shares of Integer Holdings Co. (NYSE:ITGR)

Driehaus Capital Management LLC raised its stake in shares of Integer Holdings Co. (NYSE:ITGR - Free Report) by 62.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 353,052 shares of the medical equipment provider's stock after acquiring an additional 135,750 shares during the period. Driehaus Capital Management LLC owned about 1.05% of Integer worth $40,880,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ITGR. Quest Partners LLC lifted its stake in Integer by 3,688.9% during the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 332 shares in the last quarter. GAMMA Investing LLC lifted its stake in Integer by 60.9% during the 2nd quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 142 shares in the last quarter. Headlands Technologies LLC bought a new position in Integer during the 1st quarter valued at $106,000. Innealta Capital LLC bought a new position in Integer during the 2nd quarter valued at $110,000. Finally, Hancock Whitney Corp bought a new position in Integer during the 1st quarter valued at $203,000. 99.29% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ITGR has been the subject of several research analyst reports. Oppenheimer initiated coverage on Integer in a research report on Tuesday, July 16th. They set an "outperform" rating and a $135.00 target price for the company. Benchmark reaffirmed a "buy" rating and set a $130.00 target price on shares of Integer in a research report on Friday, August 2nd. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $133.86.

Integer Stock Performance

NYSE:ITGR opened at $125.90 on Friday. The business has a 50 day moving average of $123.34 and a 200 day moving average of $119.04. The company has a market capitalization of $4.22 billion, a price-to-earnings ratio of 43.56, a PEG ratio of 1.87 and a beta of 1.09. Integer Holdings Co. has a 1-year low of $69.40 and a 1-year high of $131.87. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.29 and a quick ratio of 1.96.

Integer (NYSE:ITGR - Get Free Report) last announced its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 EPS for the quarter, topping analysts' consensus estimates of $1.24 by $0.06. The business had revenue of $436.20 million for the quarter, compared to analysts' expectations of $437.00 million. Integer had a return on equity of 11.48% and a net margin of 6.31%. The business's quarterly revenue was up 9.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.14 EPS. On average, sell-side analysts predict that Integer Holdings Co. will post 5.31 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Jean M. Hobby sold 11,960 shares of Integer stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the sale, the director now directly owns 2,280 shares in the company, valued at $272,824.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.00% of the company's stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.